Nautilus Biotechnology (NAUT) Competitors $0.76 +0.00 (+0.57%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.76 +0.00 (+0.09%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAUT vs. SENS, QSI, QTRX, FEIM, MASS, RPID, KEQU, OWLT, SEER, and PREShould you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Senseonics (SENS), Quantum-Si (QSI), Quanterix (QTRX), Frequency Electronics (FEIM), 908 Devices (MASS), Rapid Micro Biosystems (RPID), Kewaunee Scientific (KEQU), Owlet (OWLT), Seer (SEER), and Prenetics Global (PRE). These companies are all part of the "measuring and control equipment" industry. Nautilus Biotechnology vs. Its Competitors Senseonics Quantum-Si Quanterix Frequency Electronics 908 Devices Rapid Micro Biosystems Kewaunee Scientific Owlet Seer Prenetics Global Senseonics (NYSE:SENS) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Do analysts rate SENS or NAUT? Senseonics currently has a consensus price target of $1.55, suggesting a potential upside of 217.10%. Nautilus Biotechnology has a consensus price target of $2.13, suggesting a potential upside of 178.03%. Given Senseonics' stronger consensus rating and higher probable upside, analysts clearly believe Senseonics is more favorable than Nautilus Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senseonics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Nautilus Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more volatility and risk, SENS or NAUT? Senseonics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Is SENS or NAUT more profitable? Nautilus Biotechnology has a net margin of 0.00% compared to Senseonics' net margin of -362.30%. Nautilus Biotechnology's return on equity of -31.45% beat Senseonics' return on equity.Company Net Margins Return on Equity Return on Assets Senseonics-362.30% -842.25% -67.99% Nautilus Biotechnology N/A -31.45%-26.99% Which has stronger valuation & earnings, SENS or NAUT? Senseonics has higher revenue and earnings than Nautilus Biotechnology. Senseonics is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSenseonics$23.68M13.50-$60.39M-$0.11-4.44Nautilus BiotechnologyN/AN/A-$70.78M-$0.52-1.47 Do institutionals and insiders hold more shares of SENS or NAUT? 12.4% of Senseonics shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 4.3% of Senseonics shares are held by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer SENS or NAUT? In the previous week, Nautilus Biotechnology had 4 more articles in the media than Senseonics. MarketBeat recorded 4 mentions for Nautilus Biotechnology and 0 mentions for Senseonics. Nautilus Biotechnology's average media sentiment score of 1.15 beat Senseonics' score of 0.00 indicating that Nautilus Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Senseonics Neutral Nautilus Biotechnology Positive SummaryNautilus Biotechnology beats Senseonics on 9 of the 16 factors compared between the two stocks. Get Nautilus Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAUT vs. The Competition Export to ExcelMetricNautilus BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$95.87M$2.99B$5.48B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-1.4717.7428.8623.83Price / SalesN/A178.75371.4566.14Price / CashN/A41.9535.4557.96Price / Book0.468.508.265.54Net Income-$70.78M-$55.06M$3.25B$259.28M7 Day Performance0.84%-3.99%-3.75%-4.67%1 Month Performance-2.39%9.58%4.27%4.37%1 Year Performance-68.42%6.70%25.85%17.91% Nautilus Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAUTNautilus Biotechnology3.3206 of 5 stars$0.76+0.6%$2.13+178.0%-69.5%$95.87MN/A-1.47130News CoverageEarnings ReportSENSSenseonics1.6193 of 5 stars$0.54-2.2%$1.55+187.0%+21.1%$361.45M$23.68M-4.1590QSIQuantum-Si2.5254 of 5 stars$1.79-7.3%$3.48+94.1%+47.6%$354.15M$3.06M-2.63150Upcoming EarningsGap DownQTRXQuanterix2.2436 of 5 stars$6.49+10.9%$13.50+108.0%-58.3%$292.23M$137.42M-4.99460Upcoming EarningsGap DownFEIMFrequency Electronics1.0606 of 5 stars$27.87-0.4%N/A+99.3%$272.19M$69.81M11.28200Short Interest ↑Gap DownMASS908 Devices2.0915 of 5 stars$7.33-1.2%$5.33-27.2%+26.4%$266.09M$63.99M-13.5760Positive NewsUpcoming EarningsAnalyst ForecastGap DownRPIDRapid Micro Biosystems3.6118 of 5 stars$4.15+1.7%$8.00+92.8%+388.2%$178.83M$28.05M-4.03200KEQUKewaunee Scientific1.3794 of 5 stars$57.35-2.5%N/A+0.1%$173.40M$240.47M14.971,239News CoverageOWLTOwlet3.5549 of 5 stars$8.45+3.4%$10.25+21.3%+71.9%$135.01M$78.10M-5.91106News CoverageUpcoming EarningsSEERSeer2.0155 of 5 stars$2.20flat$3.00+36.4%+8.7%$129.51M$14.17M-1.56160Upcoming EarningsPREPrenetics Global2.5737 of 5 stars$8.10+0.5%$9.00+11.1%+42.6%$104.66M$30.62M-2.031News Coverage Related Companies and Tools Related Companies SENS Competitors QSI Competitors QTRX Competitors FEIM Competitors MASS Competitors RPID Competitors KEQU Competitors OWLT Competitors SEER Competitors PRE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAUT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nautilus Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
